The state of COPD in China



- Over 50 million people living with COPD¹
- Accounts for nearly 1.3 million deaths each year, or one third of total deaths from COPD globally^{1*}
- Costs close to ¥9.22 trillion (€1.2 trillion) each year^{2†}
- Direct medical costs for COPD account for **almost 10%** of total health costs^{3‡}

*2021 data †2017 data ‡2010 data

Challenges



Inequalities in COPD are magnified in rural communities; it is more prevalent and severe, and there is less access to treatment and to qualified primary care professionals.⁵⁻⁷



COPD is a highly debilitating

and often fatal lung disease⁴

Chronic obstructive pulmonary disease (COPD), which

includes emphysema and chronic bronchitis, is the

third leading cause of death worldwide (excluding

COVID-19).¹⁴ It deteriorates people's lung function – restricting their airflow, making it increasingly difficult

to breathe and potentially affecting every facet of a

person's life.⁴ The severity of the disease increases as

flare-ups that, when severe, require emergency hospital

it progresses and people with COPD can experience

admission.⁴ However, appropriate care can improve

lung health and guality of life for people with COPD.⁴

Management of COPD in primary care is inadequate. There is widespread misdiagnosis and mismanagement,⁸ limited centralised funding,⁷ and limited use of effective diagnostic tools, such as spirometry (a globally recommended diagnostic test⁴).⁹



National-level data are not routinely gathered, limiting the ability to track disease burden and evaluate the impact of different interventions on health outcomes.¹⁰

'Parents with COPD who have young children feel guilty and overwhelmed, as they often struggle to fulfil all the parental responsibilities they would want to, such as going on holidays or supporting their children in participating in outdoor sports.'

- Caregiver for a person living with COPD

Living with COPD: a caregiver's story¹¹/

fip 🔤


§The caregiver's name has been changed to respect their anonymity.

sanofi

REGENERON

Lu[§] is a caregiver for their father, who has COPD. Because the father had a history of smoking, and diagnoses of rhinitis and pharyngitis (which can also be caused by smoking), family members initially thought his symptoms might be due to those other respiratory conditions. However, when his symptoms worsened, the family sought help from the respiratory department of a tertiary hospital. He received a lung function test and was diagnosed with COPD. Since then, he has managed his condition by taking medication, living a healthy lifestyle and wearing a mask when in public.





ALLERGY & AIRWAYS

How is COPD being prioritised?

National policies

Overall status: good

COPD is included in several health policy plans.¹²

Clinical guidelines

Overall status: moderate

The Chinese Thoracic Society advises using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations for managing people with COPD;¹³ however, according to one expert, these are often followed only in larger hospitals.¹⁴

Data collection

Overall status: moderate

There is no national COPD registry. However, the government-funded China Pulmonary Health Study (2012–15) sought to estimate the prevalence and risk factors for COPD.¹⁵ This study, nonetheless, has not been repeated.

Case studies

The Enjoy Breathing **Programme patient** management model⁹

covers the whole care pathway, and provided training to nearly 100,000 primary healthcare workers between 2017 and 2023.

Specific training for respiratory care has been

introduced.¹⁶ More than 10,000 primary care institutions, 1,800 secondary hospitals and 1,600 tertiary hospitals were certified by the end of 2023.

Policymakers must take action to:



target populations and regions with a higher burden of COPD, particularly rural areas, for COPD testing and dedicated resourcing to ensure equitable access to care



mobilise and train community nurses and pharmacists to improve earlier detection of COPD (e.g. through screening guestionnaires and lung function tests) and support primary care teams in long-term management and monitoring



expand data collection on respiratory diseases to better understand the geographic burden of COPD, evaluate different interventions and understand variations in health outcomes.

Contributors

We are grateful to Prof. Chunhua Chi of Peking University First Hospital; General Practice Development Research Center, Peking University Health Science Center; and the Chinese Alliance for Respiratory Disease in Primary Care, whose valuable insights shaped the development of this country profile. We would also like to thank a caregiver for a person with COPD, who asked to remain anonymous.

References

- Global Burden of Disease Collaborative Network. 2024. Global Burden of Disease Study 2021 (GBD 2021). Institute for Health Metrics and Evaluation (IHME) Chen S, Kuhn M, Prettner K, et al. 2023. Lancet Glob Health 11(8): e1183-e93
- Chen X, Wang N, Chen Y, et al. 2016. Int J Chron Obstruct Pulm Dis: 2625-32 4.
- Global Initiative for Chronic Obstructive Lung Disease. 2024. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD
- Fang L, Gao P, Bao H, et al. 2018. Lancet Respir Med 6(6): 421-30 Kurmi OP, Davis KJ, Hubert Lam KB, et al. 2018. BMJ Open Respir Res 5(1): e000267 6
- Qian J, Ramesh M. 2024. Health Econ Policy and Law 19(1): 57-72
- 8 Sun Y-C. 2020. Chron Dis Transl Med 6(4): 219-23

- World Health Organization. https://www.who.int/news-room/feature-stories/detail/ 9. advancing-copd-care-in-china-through-a-comprehensive-approach [Accessed 19/08/24] Liu Y, Xiao S, Yin X, et al. 2022. Public Health Rev 43: 1605025 10.
- 11.
- 12.
- COPD Caregiver. 2024. Interview [Written questionnaire]. May 2024 Quan Z, Yan G, Wang Z, et al. 2021. J Thorac Dis 13(6): 3865-77 Yang T, Cai B, Cao B, et al. 2023. Ther Adv Respir Dis 17: 17534666231158283 13.
- 14.
- Chi C. 2024. Interview [Written interview]. 26/06/24 Wang C, Xu J, Yang L, *et al.* 2018. *Lancet* 391(10131): 1706-17 15.
- Fengming L. https://new.qq.com/rain/a/20240114A065QW00 [Accessed 19/08/24]

© The Health Policy Partnership, 2024. All rights reserved. Date of preparation: September 2024. Veeva ID: Z4-66527 Please cite this document as: Santoni A, Wait S, Habashi L, Whicher CH. 2024. The state of COPD in China. London: The Health Policy Partnership